ES2560327T3 - Métodos y composiciones para una velocidad de conducción nerviosa mejorada - Google Patents

Métodos y composiciones para una velocidad de conducción nerviosa mejorada Download PDF

Info

Publication number
ES2560327T3
ES2560327T3 ES11734246.9T ES11734246T ES2560327T3 ES 2560327 T3 ES2560327 T3 ES 2560327T3 ES 11734246 T ES11734246 T ES 11734246T ES 2560327 T3 ES2560327 T3 ES 2560327T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
cnv
phenyl
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11734246.9T
Other languages
English (en)
Spanish (es)
Inventor
Thomas David Mccarthy
Andrew Rainsford Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2560327T3 publication Critical patent/ES2560327T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11734246.9T 2010-01-19 2011-01-19 Métodos y composiciones para una velocidad de conducción nerviosa mejorada Active ES2560327T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29637510P 2010-01-19 2010-01-19
US296375P 2010-01-19
PCT/AU2011/000051 WO2011088504A1 (en) 2010-01-19 2011-01-19 Methods and compositions for improved nerve conduction velocity

Publications (1)

Publication Number Publication Date
ES2560327T3 true ES2560327T3 (es) 2016-02-18

Family

ID=44306296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11734246.9T Active ES2560327T3 (es) 2010-01-19 2011-01-19 Métodos y composiciones para una velocidad de conducción nerviosa mejorada

Country Status (10)

Country Link
US (1) US9095587B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525795B1 (cg-RX-API-DMAC7.html)
JP (2) JP6232184B2 (cg-RX-API-DMAC7.html)
CN (2) CN102821765A (cg-RX-API-DMAC7.html)
AU (1) AU2011207104C1 (cg-RX-API-DMAC7.html)
CA (1) CA2787173C (cg-RX-API-DMAC7.html)
ES (1) ES2560327T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ601383A (cg-RX-API-DMAC7.html)
WO (1) WO2011088504A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205375B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ605444A (en) * 2010-07-21 2015-06-26 Spinifex Pharm Pty Ltd Salt and solvates of a tetrahydroisoquinoline derivative
US10391331B2 (en) * 2011-03-29 2019-08-27 Biolyst, Llc. Systems and methods for use in treating sensory impairment
JP6232384B2 (ja) 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
JP6258867B2 (ja) 2012-01-25 2018-01-10 ノバルティス アーゲー 複素環式化合物およびその使用方法
EP2807171B1 (en) * 2012-01-25 2020-08-12 Novartis AG Heterocyclic compounds and methods for their use
NZ630908A (en) * 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
CN107001337B (zh) 2015-01-13 2021-05-04 诺华股份有限公司 作为血管紧张素ii型拮抗剂的吡咯烷衍生物
ES2898635T3 (es) 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
KR102132761B1 (ko) * 2017-06-09 2020-07-17 산동 단홍 파머수티컬 컴퍼니., 리미티드. At2r 수용체 길항제로서의 카르복시산 유도체
CN112585120B (zh) * 2018-11-02 2022-11-11 山东丹红制药有限公司 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091390A (en) * 1990-09-20 1992-02-25 E. I. Du Pont De Nemours And Company Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs
HUT71331A (en) * 1992-04-13 1995-11-28 Zeneca Ltd Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
NZ555334A (en) * 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists

Also Published As

Publication number Publication date
EP2525795B1 (en) 2015-10-21
JP2013517300A (ja) 2013-05-16
WO2011088504A1 (en) 2011-07-28
JP2016155846A (ja) 2016-09-01
CA2787173A1 (en) 2011-07-28
EP2525795A4 (en) 2013-07-24
ZA201205375B (en) 2013-09-25
CA2787173C (en) 2018-05-01
AU2011207104C1 (en) 2015-10-08
CN102821765A (zh) 2012-12-12
HK1176554A1 (en) 2013-08-02
AU2011207104A1 (en) 2012-07-26
JP6232184B2 (ja) 2017-11-15
CN107744519A (zh) 2018-03-02
EP2525795A1 (en) 2012-11-28
NZ601383A (en) 2014-07-25
US9095587B2 (en) 2015-08-04
US20130131103A1 (en) 2013-05-23
AU2011207104B2 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
EP0237522B1 (en) Pharmaceutically active derivatives of tryptophan and pharmaceutical compositions containing them
JP2004524337A (ja) 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用
BRPI0710737A2 (pt) uso de compostos pb-10 33 éteis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos
CA2787173C (en) Methods and compositions for improved nerve conduction velocity
ES2389500T3 (es) Agente protector para una célula neuronal retiniana que contiene un derivado de prostaglandina F2 alfa como ingrediente activo
JPS5841821A (ja) 最少化された胃の損傷を示す抗炎症組成物
AU2011232341B2 (en) Improved stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
ES2388876T3 (es) Uso de [2-(2-metilimidazol-1-il)metil]piridina para tratamiento de trastornos del sueño
WO2020055226A1 (es) Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
US6545057B2 (en) Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
KR102927058B1 (ko) 진통 가려움 완화 약학 조성물 및 그 응용 방법
ES2280505T3 (es) Composicion farmaceutica que comprende gamma-butirobetaina.
HUP0100599A2 (hu) Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen
KR102900174B1 (ko) 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN109758453A (zh) 胺类化合物治疗焦虑障碍的医药用途
JPH11511479A (ja) 1,2,4−ベンゾトリアジンオキシド製剤
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
JP2010518160A (ja) 粘膜の疾患による組織の崩壊、傷害又は損傷を治療又は予防する方法
ES2738706T3 (es) Composiciones que comprenden finafloxacina y Tris
WO2003084482A2 (en) Antidepressants and their analogues as long-acting local anesthetics and analgesics
KR102952931B1 (ko) 포르피린증의 예방 또는 치료제
AU2009331469A1 (en) 5-HT2A and 5-HT2B receptor antagonists for treating stenosis of the spinal canal
ES2277787B1 (es) Empleo de tioprolina en tratamientos de reduccion de peso corporal.
KR102161787B1 (ko) 수면 장애의 예방 또는 치료용 약학적 조성물